Difficult to Manage, or Difficult to See? Save
When axSpA does not respond to treatment and both the clinician and patient perceive this is a problem, we call it difficult to manage. Is the disease difficult, or are we failing to see it clearly?
The ASAS points to consider for difficult to manage, including treatment refractory, axSpA contain four overarching principles and ten points, endorsed by 91.3% of ASAS full members [2944]. The key distinction is between difficult to manage disease, which may arise from factors related or unrelated to inflammation, and treatment refractory disease, defined by persistent objective inflammation despite appropriate therapy.
The sequence is to reassess the diagnosis, confirm inflammation with MRI, ultrasound or acute phase reactants. Check adherence in its social context, manage uveitis, IBD and psoriasis with specialist colleagues. Look for mimics, from nociplastic pain and degenerative disease to sleep disorders, depression and obesity. Only then consider a new mechanism, dose optimisation or combination targeted therapy. Objective confirmation of inflammation drew the lowest agreement of any statement, perhaps a reflection of limited MRI access.
For truly refractory disease, combination therapy is moving from case report to cohort studies. In French national data, 2,955 people starting combination targeted therapy across 28 immune mediated diseases showed no increase in serious infection (HR 0.91), cancer (HR 0.67) or death (HR 1.05) compared with monotherapy [0354]. In a Spanish cohort of 76 refractory SpA and PsA patients on dual targeted therapy, 55.6% reached remission during follow up [1322].
Seeing clearly starts with definitions. In the DESIR cohort, the 2025 ASAS SPARTAN criteria classified 44% of 663 patients with early axSpA, against 63% for the 2009 ASAS criteria [2347]. The clinical arm fell from 30.1% to 0.8%, and those missed were almost all HLA B27 positive. Classification criteria are not diagnostic criteria, but they decide who enters trials, and trials decide which evidence we have.
Read against the ASAS framework, other ACR26 posters supply the tools: a pain phenotype screen for nociplastic features, antibody testing at TNF inhibitor failure, calprotectin for occult gut inflammation and joint clinics that can approve combination therapy [1337, 2284, 1336, 2287]. Together they turn a consensus statement into a clinic pathway.
Difficult to manage axSpA is exactly where guideline text runs out and judgement matters most. Before calling a patient refractory, check that we have seen them clearly: the right diagnosis, real inflammation, the right history and the whole person. Difficult to manage is sometimes a description of the disease, and sometimes a description of us.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.